Torrent Pharmaceuticals Ltd

Net profit of Torrent Pharmaceuticals rose 30.46% to Rs 591.00 crore in the quarter ended September 2025 as against Rs 453.00 crore during the previous quarter ended September 2024. Sales rose 14.66% to Rs 3246.00 crore in the quarter ended September 2025 as against Rs 2831.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3246.002831.00 15 OPM %33.3633.17 - PBDT1008.00859.00 17 PBT804.00661.00 22 NP591.00453.00 30 Powered by Capital Market - Live

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting at Rs 3586.6, up 0.06% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25868.7. The Sensex is at 84424.21, up 0.56%. Torrent Pharmaceuticals Ltd has dropped around 1.9% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has dropped around 0.15% in last one month and is currently quoting at 22253.75, up 0.65% on the day. The volume in the stock stood at 49750 shares today, compared to the daily average of 3.07 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 3593.6, up 0.36% on the day. Torrent Pharmaceuticals Ltd is up 5.72% in last one year as compared to a 4.39% gain in NIFTY and a 3.13% gain in the Nifty Pharma index.The PE of the stock is 60.93 based on TTM earnings ending June 25.Powered by Capital Market - Live

Torrent Pharmaceuticals has allotted commercial paper aggregating Rs 200 crore on 24 September 2025. Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quoting at Rs 3655.5, up 0.72% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 25304.8. The Sensex is at 82459.38, down 0.2%. Torrent Pharmaceuticals Ltd has slipped around 0.52% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has slipped around 0.46% in last one month and is currently quoting at 22686.6, down 0.97% on the day. The volume in the stock stood at 81558 shares today, compared to the daily average of 1.84 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 3661, up 0.7% on the day. Torrent Pharmaceuticals Ltd is up 5.72% in last one year as compared to a 2.45% slide in NIFTY and a 2.89% slide in the Nifty Pharma index.The PE of the stock is 61.82 based on TTM earnings ending June 25.Powered by Capital Market - Live

According to an exchange filing, the inspection was conducted from 28 July to 1 August 2025. The company reported that the inspection concluded with zero observations. Torrent Pharmaceuticals is the flagship of the Torrent Group and ranks seventh in the Indian pharmaceutical market. It is among the top five players in key therapeutic areas such as cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology. With nearly 76% of its India business coming from chronic and sub-chronic therapies, Torrent remains a focused, specialty-driven player. The pharma major reported a net profit of Rs 548 crore in Q1 FY25, marking a 20% year-on-year increase. Revenue for the quarter stood at Rs 3,178 crore, an 11% rise over Q1 FY25. The scrip slipped 1.34% to Rs 3,624.85 on the BSE. Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 3758.6, up 3.75% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 24701.85. The Sensex is at 80911.87, up 0.03%. Torrent Pharmaceuticals Ltd has gained around 10.28% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has gained around 4.35% in last one month and is currently quoting at 22761.15, up 1.04% on the day. The volume in the stock stood at 11.8 lakh shares today, compared to the daily average of 6.26 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 3766.6, up 3.95% on the day. Torrent Pharmaceuticals Ltd is up 20.81% in last one year as compared to a 0.63% slide in NIFTY and a 6.77% slide in the Nifty Pharma index.The PE of the stock is 64.84 based on TTM earnings ending March 25.Powered by Capital Market - Live

The pharma major reported a net profit of Rs 548 crore, marking a 20% year-on-year increase, driven by resilient revenues and steady margins. Revenue for the quarter stood at Rs 3,178 crore, an 11% rise over Q1 FY25, supported by improved operational leverage. International markets played a key role in the growth story. Sales in the United States rose 19% to Rs 308 crore. India, Torrent's largest market, contributed Rs 1,811 crore, growing 11% year-on-year. Brazil matched that growth with an 11% rise, while Germany posted a 9% increase. Revenue from other global markets was also healthy, rising 10% YoY. On the operational front, EBITDA grew 14% YoY to Rs 1,032 crore, translating into a margin of 32.5%. Adjusting for one-time acquisition-related expenses of Rs 15 crore, the margin edged higher to 32.9%. Gross margins remained firm at 76% in Q1 FY26. The company also continued to back its R&D engine, spending Rs 157 crore during the quarter, a 16% increase over last year, while maintaining the R&D-to-sales ratio at 5%. Torrent's performance drew praise from analysts. A foreign brokerage firm raised its price target on the stock to Rs 4,380 from Rs 4,000, citing the quarter as healthy and in-line, with solid traction across geographies. The firm maintained its 'Buy' rating, reflecting optimism over the company's steady execution and global growth outlook. Torrent Pharmaceuticals is the flagship of the Torrent Group and ranks seventh in the Indian pharmaceutical market. It is among the top five players in key therapeutic areas such as cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology. With nearly 76% of its India business coming from chronic and sub-chronic therapies, Torrent remains a focused, specialty-driven player. Powered by Capital Market - Live

Net profit of Torrent Pharmaceuticals rose 19.91% to Rs 548.00 crore in the quarter ended June 2025 as against Rs 457.00 crore during the previous quarter ended June 2024. Sales rose 11.12% to Rs 3128.00 crore in the quarter ended June 2025 as against Rs 2815.00 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales3128.002815.00 11 OPM %32.9932.11 - PBDT939.00853.00 10 PBT738.00656.00 13 NP548.00457.00 20 Powered by Capital Market - Live

The Board of Torrent Pharmaceuticals at its meeting held on 28 July 2025 has approved the issuance of Unsecured / Secured Redeemable Non-Convertible Debentures / Bonds by way of private placement within the borrowing limits of the Company. Powered by Capital Market - Live